Haemoglobin A1c: Historical overview and current concepts

Diabetes Research and Clinical Practice

Volumn 99, Issue 2, 2013, Pages 75-84

  Lenters Westra, Erna ^a,b   Schindhelm, Roger K ^c   Bilo, Henk J ^a,d   Slingerland, Robbert J ^a,b  

^a Isala Klinieken ^*  (Netherlands)

^b European Reference Laboratory for Glycohaemoglobin   (Netherlands)

^c Location Alkmaar   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Diabetes mellitus; HbA1c; Methods; Standardisation

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C;

AMINO TERMINAL SEQUENCE; CATION EXCHANGE; CELL SURVIVAL; CONTROLLED STUDY; COVALENT BOND; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; LIFESPAN; NON INSULIN DEPENDENT DIABETES MELLITUS; POINT OF CARE TESTING; REVIEW; STANDARDIZATION;

ANIMALS; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MODELS, BIOLOGICAL;

EID: 84876742599     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.10.007     Document Type: Review

References (75)

1. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
2. Wang Y., Mi J., Shan X.Y., Wang Q.J., Ge K.Y. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 2007, 31:177-188.
3. Yoon K.H., Lee J.H., Kim J.W., Cho J.H., Choi Y.H., Ko S.H., et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006, 368:1681-1688.
4. Beran D., Yudkin J.S. Diabetes care in sub-Saharan Africa. Lancet 2006, 11(368):1689-1695.
5. Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
6. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
7. Stirban A.O., Tschoepe D. Cardiovascular complications in diabetes: targets and interventions. Diabetes Care 2008, 31(Suppl. 2):S215-S221.
8. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332:73-78.
9. Jansson S.P., Andersson D.K., Svärdsudd K. Mortality trends in subjects with and without diabetes during 33 years of follow up. Diabetes Care 2010, 33:551-556.
10. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
11. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
12. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl. 2):S62-S69.
13. Jeppsson J.O., Kobold U., Barr J., Finke A., Hoelzel W., Hoshino T., et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002, 40:78-89.
14. Sacks D.B., ADA/EASD/IDF Working Group of the HbA1c Assay Global harmonization of hemoglobin A1c. Clin Chem 2005, 51:681-683.
15. Consensus Committee Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007, 30:2399-2400.
16. Weykamp C., John W.G., Mosca A., Hoshino T., Little R., Jeppsson J.O., et al. The IFCC reference measurement system for HbA1c: a 6-year progress report. Clin Chem 2008, 54:240-248.
17. Report of a World Health Organization Consultation Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Diabetes Res Clin Pract 2011, 93:299-309.
18. Rahbar S. An abnormal haemoglobin in red cells of diabetics. Clin Chim Acta 1968, 22:296-298.
19. Rahbar S., Blumenfeld O., Ranney H.M. Studies of an unusual haemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun 1969, 36:838-845.
20. Bunn H.F., Haney D.N., Kamin S., Gabbay K.H., Gallop P.M. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest 1976, 57:1652-1659.
21. Bunn H.F., Gabbay K.H., Gallop P.M. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978, 200:21-27.
22. 1c in normal and diabetic subjects. J Clin Invest 1976, 58:3892-3898.
23. Cohen R.M., Franco R.S., Khera P.K., Smith E.P., Lindsell C.J., Ciraolo P.J., et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008, 112:4284-4291.
24. Leslie R.D.G., Cohen R.M. Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications. J Diabetes Sci Technol 2009, 3:635-643.
25. Jeffcoate S.L. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 2004, 21:657-665.
26. Henrichs H.R. HbA1c-glycated hemoglobin and diabetes mellitus 2009, UNI-MED, Bremen. 1st ed.
27. Gallagher E.J., Le Roith D., Bloomgarden Z. Review of hemoglobin A1c in the management of diabetes. J Diabetes 2009, 1:9-17.
28. Braga F., Dolci A., Mosca A., Panteghini M. Biological variability of glycated hemoglobin. Clin Chim Acta 2010, 411:1606-1610.
29. Trivelli L.A., Ranney H.M., Lai H.T. Hemoglobin components in patients with diabetes mellitus. N Engl J Med 1971, 284:353-357.
30. Bunn H.F., Haney D.N., Gabbay K.H., Gallop P.M. Further identification of the nature and linkage of the carbohydrate in haemoglobin A1c. Biochem Biophys Res Commun 1975, 67:103-109.
31. John G.W., Mosca A., Weykamp C.W., Goodall I. HbA1c standardisation: history, science and politics. Clin Biochem Rev 2007, 58:163-168.
32. WHO Diabets Mellitus: Report of a Study Group. Technical report series 727. Geneva: World Health Organization; 1985.
33. Goodall I. HbA1c standardisation destination - global IFCC standardisation how, why, where and when. Clin Biochem Rev 2005, 26:5-19.
34. Chapelle J.P., Teiveira J., Maisin D., Assink H., Barla G., Stoobants A.K., et al. Multicentre evaluation of the Tosoh HbA1c G8 analyser. Clin Chem Lab Med 2010, 411:1606-1610.
35. Weykamp C.W., Lenters-Westra E., Van der Vuurst H., Slingerland R.J., Siebelder C., Visser-Dekker W. Evaluation of the Menarini/ARKRAY ADAMS A1c HA-8180V analyser for HbA1c. Clin Chem Lab Med 2011, 49:647-651.
36. Little R.R., Roberts W.L. A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol 2009, 3:446-451.
37. [accessed September 2012]. http://www.trinitybiotech.com/HbA1c_HB/Pages/BoronateAffinity.aspx.
38. Weykamp C.W., Penders T.J., Muskiet F.A.J., Van der Slik W. Influence of haemoglobin variants and derivatives on glycohaemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 1993, 39:1717-1723.
39. National Glycohemoglobin Standardization Program. HbA1c assay interferences. [accessed February 2011]. http://www.ngsp.org/interf.asp.
40. Rohlfing C.L., Connolly S.M., England J.D., Hansson S.E., Moellering C.M., Bachelder J.R., et al. The effect of elevated fetal hemoglobin on hemoglobin A1c results. Am J Clin Pathol 2008, 129:811-814.
41. National Glycohemoglobin Standardization Program. College of American Pathologists (CAP) GH2 Survey Data. [accessed September 2012]. http://www.ngsp.org/CAP/CAP10a.pdf.
42. Fleming J.K. Evaluation of HbA1c on the COBAS Integra 800 closed tube system. Clin Biochem 2007, 40:822-827.
43. Schindhelm R.K., Lenters-Westra E., Fokkert M.J., Slingerland R.J. Glucose and glycated haemoglobin point-of-care testing and early diagnosis of diabetes and pre-diabetes. Eur Endocrinol 2010, 6:24-28.
44. Cagliero E., Levina E.V., Nathan D.M. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care 1999, 22:1785-1789.
45. Ferenczi A., Reddy K., Lorber D.L. Effect of immediate haemoglobin A1c results on treatment decisions in office practice. Endocr Pract 2001, 7:85-88.
46. Miller C.D., Barnes C.S., Phillips L.S., Ziemer D.C., Gallina D.L., Cook C.B., et al. Rapid A1c availability improves clinical decision-making in an urban primary care clinic. Diabetes Care 2003, 26:1158-1163.
47. Lenters-Westra E., Slingerland R.J. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem 2010, 56:44-52.
48. National Glycohemoglobin Standardization Program. Background. [accessed September 2012]. http://www.ngsp.org/bground.asp.
49. The DCCT Research Group Feasibility of centralized measurements of glycated hemoglobin in the diabetes control complication trial: a multi centre study. Clin Chem 1987, 33:2267-2271.
50. National Glycohemoglobin Standardization Program. NGSP protocol. [accessed September 2012]. http://www.ngsp.org/protocol.asp.
51. Approved Laboratories of the IFCC Network Laboratories for HbA1c. [accessed September 2012]. http://www.ifcchba1c.net/IFCC_01.asp?type=N.
52. Finke A., Kobold U., Hoelzel W., Weycamp C., Jeppsson J.O., Miedema K. Preparation of a candidate primary reference material for the international standardisation of HbA1c determinations. Clin Chem Lab Med 1998, 36:299-308.
53. The IFCC HbA1c Network. Introduction. [accessed September 2012]. http://www.ifcchba1c.net/index.asp.
54. Eckerbom S., Bergqvist Y., Jeppsson J.O. Improved method for analysis of glycated haemoglobin by ion exchange chromatography. Ann Clin Biochem 1994, 31:355-360.
55. Shima K., Endo J., Oimomi M., Oshima I., Omori Y., Katayama Y., et al. International differences in HbA1c measurement in Japan, an interim report of the committee on an interlaboratory standardization of HbA1c determination. J Jpn Diab Soc 1994, 37:233-243.
56. Shima K., Endo J., Oimomi M., Omori Y., Katayama Y., Kanazawa Y., et al. International differences in GHb measurement in Japan, the fifth report of the GHb Standardization Committee, the Japan Diabetes Society. J Jpn Diab Soc 1998, 41:317-323.
57. Hoelzel W., Weykamp C., Jeppsson J.O., Miedema K., Barr J.R., Goodall I., et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan and Sweden: a method comparison study. Clin Chem 2004, 50:166-174.
58. Geistanger A., Arends S., Berding C., Hoshino T., Jeppsson J.O., Little R., et al. On behalf of the IFCC Working Group on Standardization of HbA1c: Statistical methods for monitoring the relationship between the IFCC reference measurement procedure for hemoglobin A1c and the designated comparison methods in the United States, Japan and Sweden. Clin Chem 2008, 54:1379-1385.
59. Weykamp C., John G.W., Mosca A., Hoshino T., Little R., Jeppsson J.O., et al. The IFCC reference measurement system for HbA1c: a 6-year progress report. Clin Chem 2008, 54:240-248.
60. Mosca A., Goodall I., Hoshino T., Jeppsson J.O., John W.G., Little R.R., et al. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med 2007, 45:1077-1080.
61. Hanas R. Psychological impact of changing the scale of reported HbA1c results affects metabolic control. Diabetes Care 2002, 25:2110-2111.
62. Nathan D.M., Kuenen J., Borg R., Zheng H., Schoenfeld D., Heine R.J., et al. Translating the A1c assay into estimated average glucose values. Diabetes Care 2008, 31:1-6.
63. The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation Diabetes Care 2007, 30:2399-2400.
64. Young I.S. Counterpoint: the reporting of estimated glucose with hemoglobin A1C. Clin Chem 2010, 56:547-549.
65. Sacks D.B., Bergenstal R.M., McLaughlin S. Point: the reporting of estimated glucose with hemoglobin A1C. Clin Chem 2010, 56:545-546.
66. Barth J.H., Marshall S.M., Watson I.D. Consensus meeting on reporting glycated haemoglobin (HbA1c) and estimated average glucose (eAG) in the UK: report to the National Director for Diabetes, Department of Health. Diabet Med 2008, 25:381-382.
67. Hagnar R., John G. 2010 consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Diabetes Care 2010, 33:1903-1904.
68. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
69. Standards of medical care in diabetes 2010. Diabetes Care 2010, 33(Suppl. 1):S11-S61.
70. Rohlfing C., Wiedmeyer H.M., Little R., Grotz V.L., Tennill A., England J., et al. Biological variation of glycohemoglobin. Clin Chem 2002, 48:1116-1118.
71. Omar F., van der Watt G.F., Pillay T.S. Reference change values: how useful are they?. J Clin Pathol 2008, 61:426-427.
72. Ricos C., Cava F., Garcia-Lario J.V., Hernández A., Iglesias N., Jiménez C.V., et al. The reference change value: a proposal to interpret laboratory reports in serial testing based on biological variation. Scand J Clin Lab Invest 2004, 64:175-184.
73. U.S. Food and Drug Administration. Definition CLIA waived tests. [assessed June 2012]. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm124202.htm.
74. Bruns D.E., Boyd J.C. Few point-of-care hemoglobin A1c assay methods meet clinical needs. Clin Chem 2010, 56:4-6.
75. Lenters-Westra E., Weykamp C.W., Schindhelm R.K., Siebelder C., Bilo H.J., Slingerland R.J. One in five laboratories using various hemoglobin A1c methods do not meet the criteria for optimal diabetes care management. Diabetes Technol Ther 2011, 13:429-433.